The extension could trigger up to $41m research payments to Evotec.
Evotec chief operating officer Dr Mario Polywka said, "This collaboration is an excellent example of how companies, including foundations such as CHDI, can access Evotec’s platform suite of technologies, capabilities and strong disease biology expertise, to drive their drug discovery efforts."
As a part of the research partnership, Evotec is contributing its drug discovery platform, knowledge in neurological research, and related capabilities in medicinal chemistry, in vitro and in vivo pharmacology, and compound management.
CHDI chief scientific officer Dr Robert Pacifici said CHDI partners with a global network of investigators from the academic, biopharmaceutical, and service sectors to execute the drug discovery and development efforts.
"Evotec represents one of our largest and longest standing relationships with a contract research organization," Dr Pacifici added.